Szlovénia -
szlovén -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
hydroxyurea medac 500 mg kapsule
hidroksisečnina - kapsula, trda - hidroksisečnina 500 mg / 1 kapsula - hidroksisečnina
Európai Unió -
szlovén -
EMA (European Medicines Agency)
velphoro
vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - zdravila za zdravljenje hyperkalemia in hyperphosphatemia - velforo je indiciran za nadzor ravni serumskega fosforja pri bolnikih s kronično boleznijo ledvic (ckd) pri hemodializi (hd) ali peritonealni dializi (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.
Európai Unió -
szlovén -
EMA (European Medicines Agency)
hexyon
sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - cepiva - hexyon (dtap-ipv-hb-hib) je indicirano za osnovno in obnovitveno cepljenje dojenčkov in malčkov iz šestih tednih starosti proti davici, tetanus, oslovski kašelj, hepatitis b, otroški ohromelosti in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b (hib). uporaba tega cepiva mora biti v skladu z uradnimi priporočili.
Európai Unió -
szlovén -
EMA (European Medicines Agency)
kolbam
retrophin europe ltd - holinska kislina - presnova, urojene napake - terapija z jetri in jeter - cholic kisline fgk je primerna za zdravljenje prirojeno napake primarnih žolčnih kislin sintezo, pri otrocih od enega meseca starosti za stalno vseživljenjsko zdravljenje do odrasle dobe, ki zajema naslednje en encim napake:sterol 27-hydroxylase (predstavitev, kot cerebrotendinous xanthomatosis, ctx) pomanjkljivosti;2- (ali alfa-) methylacyl-coa racemase (amacr) pomanjkljivosti;holesterola 7 alfa-hydroxylase (cyp7a1) pomanjkanje.
Európai Unió -
szlovén -
EMA (European Medicines Agency)
adakveo
novartis europharm limited - crizanlizumab - anemija, srčna celica - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
Európai Unió -
szlovén -
EMA (European Medicines Agency)
klisyri
almirall, s.a. - tirbanibulin - keratoza, aktinik - antibiotiki in kemoterapevtiki za dermatološko uporabo - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.
Európai Unió -
szlovén -
EMA (European Medicines Agency)
jakavi
novartis europharm limited - ruksolitinib (kot fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastična sredstva - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi je indiciran za zdravljenje odraslih bolnikov z polycythaemia vera, ki so odporne ali nestrpne hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.